Brought to you by 
Isotechnika, Aurinia merge
23 Sep 2020
Executive Summary
Isotechnika Pharma Inc. (immunomodulating therapeutics) has agreed to acquire Aurinia Pharmaceuticals Inc. (lupus and nephrology drug candidate), forming a global nephrology firm that will keep the Aurinia name. Istoechnika will own 65% of the company post-merger.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Isotechnika, Aurinia merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice